Hematologic Malignancies

ASH 2024

Questions discussed in this category

With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?

Based on AALL1731, if in maintenance, is there a certain point at which it is incorporated, or a certain maintenance cycle which it is no longer offer...

1 Answer available

Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?

AQUILA trial - NEJM

3 Answers available

Papers discussed in this category

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood cancer journal, 2020 Oct 16

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Hematologic Malignancies

ASH 2024

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematologic Malignancies